ConductScience.org, home

Paper8709686

Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee.

Lancet, 1996. Cited by 266 papers, by iCite.

Cite this record

ConductScience Library. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee. Papers, record 8709686. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8709686

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee.
PubMed
Journal
Lancet
PubMed
Year
1996
PubMed
Publication types
Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
266
iCite
Relative citation ratio, by iCite
7.67
iCite
Revised in PubMed
2015-06-16
PubMed

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antiviral AgentsMajor topic
DidanosineMajor topic
HIV InfectionsMajor topic
ZalcitabineMajor topic
ZidovudineMajor topic
Adolescent
Adult
CD4 Lymphocyte Count
Disease Progression
Double-Blind Method
Drug Therapy, Combination
Female
Follow-Up Studies
Humans
Male
Survival Analysis

Source PubMed

Download CSV of topics

Comments and corrections4

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in8709681Delta in the real world.https://conductscience.org/library/papers/8709681PubMed
Comment in8898046The Delta trial.https://conductscience.org/library/papers/8898046PubMed
Comment in8898047The Delta trial.https://conductscience.org/library/papers/8898047PubMed
Comment in11556343Liver failure after long-term nucleoside antiretroviral therapy.https://conductscience.org/library/papers/11556343PubMed

Download CSV of comments and corrections

Cited by54

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 266 citations.

PMIDTitleJournalYearIn PapersSource
36796006[Medical Care of people living with HIV in the Instituto Mexicano del Seguro Social].Rev Med Inst Mex Seguro Soc2022https://conductscience.org/library/papers/36796006PubMed
36130204New antiretroviral inhibitors and HIV-1 drug resistance: more focus on 90% HIV-1 isolates?FEMS Microbiol Rev2023https://conductscience.org/library/papers/36130204PubMed
35491570The best backbone for HIV prevention, treatment, and elimination: Emtricitabine+tenofovir.Antivir Ther2022https://conductscience.org/library/papers/35491570PubMed
35399147
Shorter Time to Discontinuation Due to Treatment Failure in People Living with HIV Switched to Dolutegravir Plus Either Rilpivirine or Lamivudine Compared with Integrase Inhibitor-Based Triple Therapy in a Large Spanish Cohort.
Infect Dis Ther2022https://conductscience.org/library/papers/35399147PubMed
34726308Marine mollusc extracts-Potential source of SARS-CoV-2 antivirals.Rev Med Virol2022https://conductscience.org/library/papers/34726308PubMed
32854292Promoting Undetectable Equals Untransmittable in Sub-Saharan Africa: Implication for Clinical Practice and ART Adherence.Int J Environ Res Public Health2020https://conductscience.org/library/papers/32854292PubMed
32659363Achieving effective informed oversight by DMCs in COVID clinical trials.J Clin Epidemiol2020https://conductscience.org/library/papers/32659363PubMed
29860311PAK1 regulates ATXN1 levels providing an opportunity to modify its toxicity in spinocerebellar ataxia type 1.Hum Mol Genet2018https://conductscience.org/library/papers/29860311PubMed
29340087Identification of antipsychotic drug fluspirilene as a potential anti-glioma stem cell drug.Oncotarget2017https://conductscience.org/library/papers/29340087PubMed
29339063Evolution of Intravitreal Therapy for Retinal Diseases-From CMV to CNV: The LXXIV Edward Jackson Memorial Lecture.Am J Ophthalmol2018https://conductscience.org/library/papers/29339063PubMed
28775605THERAPY AND PROPHYLAXIS IN HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION.Med J Armed Forces India1999https://conductscience.org/library/papers/28775605PubMed
22996358[Morbidity and mortality in HIV infection].Internist (Berl)2012https://conductscience.org/library/papers/22996358PubMed
21694884New approaches in the management of chronic hepatitis B: role of tenofovir.Infect Drug Resist2009https://conductscience.org/library/papers/21694884PubMed
21182347Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK.Pharmacoeconomics2010https://conductscience.org/library/papers/21182347PubMed
20624077Incident neuropathy in HIV-infected patients on HAART.AIDS Res Hum Retroviruses2010https://conductscience.org/library/papers/20624077PubMed
19825136Disease Management - Constructing Optimal NRTI-Based Combinations: Past, Present, and Future.J Int AIDS Soc2006https://conductscience.org/library/papers/19825136PubMed
19361855Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.Lancet2009https://conductscience.org/library/papers/19361855PubMed
18472979The renaissance of fixed dose combinations: Combivir.Ther Clin Risk Manag2007https://conductscience.org/library/papers/18472979PubMed
18004087Liver enzymes elevation and immune reconstitution among treatment-naïve HIV-infected patients instituting antiretroviral therapy.Am J Med Sci2007https://conductscience.org/library/papers/18004087PubMed
17053925[Antiviral treatment regimens].Hautarzt2006https://conductscience.org/library/papers/17053925PubMed

See all 54 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
CD4920PubTator's text mininghttps://conductscience.org/library/genes/920

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Authors
  • Grants
  • Trials
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/8709686

GET https://conductscience.org/api/papers/v1/8709686/cited_by?page=2